# Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-28 11:29 UTC · Category: Business · Sources: 6 · Current Velocity: 3.67

## Intelligence Brief
"Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by Fierce Pharma, WSJ, FirstWord Pharma and Reuters. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| BioSpace | Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxNOHM4bGdqeXVhVnJaMjBmSEdXMlo2ODJYU3RiT2RfRURldGo2ejFnajJLejE3SHJXZmdNclJwQllHdVZuTmNmOTM0U3AybzI4ZEs1R3VHamZ3WEtnMkF6bGRUVFpKUUxWdHNJQjN6M2lOdWNlbWFtS0RpUW9EQ3Z4QXlxcWYtc19BSnpVSE9SdzhXU1hDZHVWMTVCTzVnWmYwYWN1Y2lrSVY4dC12S0JXSQ?oc=5) |
| Fierce Pharma | Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxQRkRaVUs2ME9YWGhWTXpPZTFhVS10djhocGhXbmU4Yk9hQ0dpb255Q0wzOFQwTEJaTXZMcUlPam1qcVFodzZXSXk0TlhlbTF2ZjdHcjItWlJBcEpOTTBvWkZNektWUkotb1NEbV9aNlU3bnpZUGVOeDlpbjRVX2p0ZGdJWkVMWE9FUXlDRlJPZzdEWWZyZ0NrYjQ2RG02REUzOEprNGRUbVlvRmlscXhuV1F3M2R6MWpVX2pBdw?oc=5) |
| WSJ | Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxOaVFMeFV6aEp4TlZ0cGg2SVBPSVoxTlp5cnlFLTl5TU16QUtBeXNfcFFMelg3QUg2WVkwdmFpbXpqNDZYcmJxNWFJcFhNRU90MWhSdzZNejFNeVVTd21ZeHZKZnk2SU5OZWhURXpmVHpkWXJ4V01iRDh6MnBKQ1RXb2JTSjhOVmFURVF6ejlYcURla2NLUl9rcnNRMmdyVGlndlRBSTZweWpuTmU5Nmc?oc=5) |
| FirstWord Pharma | Novartis lifts annual profit guidance despite $1.9B hit from del-desiran failure | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE0xVWdxRXVXcXZTMjdQeTBrSDZLczZKV3Fkam1YSWlyS1JYcHJWNmh3WHFfcHNMR2h3ak9PU2pxVWVCOG5FRFExTW85aWRfVW5FRkpz?oc=5) |
| Reuters | Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxORGNqcHZHNndLNXNGbW1HaUNsU2tDUm9aS3pLNFYtRGZPckNKbEgxcVlVRDN4QmF2dDQ4YlVZa05FRzBlcGtvNkF5Y191Vzc2cE5VaHlfMEFoLWt2RFBNc0RvUHNTQlZQQlJhR21TUEhNQXJXZlEyTUNhUXd0S1BwUWRhNG51dVpCSERJV1Rab0N0S0pFV3V5RUFRNmd6RzNuWWVGTVZKRjJaaUpSYXlPNFlzZm12YTQyWDNCWng1UUpYR3hVYlUw?oc=5) |
| Fierce Biotech | Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail | 2026-10-27 07:48 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPMnNYTTVJcHEybndQTlVRLVhCVzBQT0JLZER1cFhPTnVaRFVDQlhsWU9sLXloNDFNTk1YekstOTFjTnRFdzREQ1h6RUZZOE9XZTd3TUJDNlhtcE9wVFJ1VWs2NTZiUC1aNlhQLXF6SlF2QjJMamgtT3NkbmdLbmhIZW9Md2tlSHZoWTV3Y3NTbW96Q0NuU3hRTUpBLURDbkpTU1U5TGlTRmlOLW9a?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-28/novartis-ceo-keeps-faith-in-avidity-deal-despite-taking-1-9b-hit-from-del*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*